IP Library Granted Patent US 7,202,330
Granted Patent B2
US 7,202,330 · App. 10/258,766 · Granted Apr 10, 2007

RGD (Arg-Gly-Asp) coupled to (neuro)peptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,202,330
App. No.
10/258,766
Granted
Apr 10, 2007
Kind
B2
Abstract

The invention relates to compounds having a binding affinity for both the αvβ3 receptor and a (neuro)peptide receptor, in particular the somatostatin receptor, which compound comprises a first peptide part comprising at least once the amino acid sequence Arg-Gly-Asp, and a second peptide part coupled thereto, optionally via a linker, which second peptide part is a (neuro)peptide.

Claims (8)

1. A compound comprising a somatostatin receptor binding peptide or analog thereof that binds to a somatostatin receptor, a linker amino acid at the N-terminus of said somatostatin receptor binding peptide, a metal chelating group coupled to said linker and an apoptosis-inducing molecule comprising an amino acid sequence Arg-Gly-Asp-DTyr-Asp wherein the N-terminal Arg and the C-terminal Asp of said amino acid sequence are cyclized, and wherein the C-terminal Asp of said amino acid sequence is coupled to said linker amino acid.

2. The compound as in claim 1 , wherein said apoptosis-inducing molecule activates Caspase-3.

3. The compound as in claim 1 , wherein said somatostatin analog is selected from the group consisting of octreotate, octreotide, lantreotide, vapreotide, and derivatives thereof.

4. The compound as in claim 1 , wherein said metal chelating group is a metal chelating group suitable for radiolabeling.

5. The compound as in claim 4 , wherein said linker amino acid is lysine, para-amino phenylalanine, or diamino propionic acid.

6. The compound as in claim 4 , wherein said metal chelating group suitable for radiolabeling is DTPA or DOTA.

7. The compound as in claim 4 , wherein said metal chelating group is radiolabeled with a radioisotope selected from the group consisting of 213 Bi, 186 Re, 188 Re, 77 As, 90 Y, 6 Ga, 67 Cu, 169 Er, 114 In, 117m Sn, 121 Sn, 127 Te, 142 Pr, 143 Pr, 198 Au, 199 Au, 149 Tb, 161 Tb, 109 Pd, 165 Dy, 149 Pm, 151 Pm, 153 Sm, 157 Gd, 159 Gd, 166 Ho, 172 Tm, 169 Yb, 175 Yb, 177 Lu, 105 Rh, 103m Rh, 195m Pt, 111 Ag, 124 I, 131 I, 121 At, 99m Tc, 203 Pb, 67 Ga, 68 Ga, 72 As, 111 In, 13m In, 97 Ru, 62 Cu, 64 Cu, 52 Fe, 52m Mn, 51 Cr, 123 I, 131 I, 75 Br, 76 Br, 77 Br, and 82 Br.

8. The compound as in claim 6 , wherein said metal chelating group is radiolabeled with a radioisotope selected from the group consisting of 213 Bi, 186 Re, 188 Re, 77 As, 90 Y, 6 Ga, 67 Cu, 169 Er, 114m In, 117m Sn, 121 Sn, 127 Te, 142 Pr, 143 Pr, 198 Au, 199 Au, 149 Tb, 161 Tb, 109 Pd, 165 Dy, 149 Pm, 151 Pm, 153 Sm, 157 Gd, 159 Gd, 166 Ho, 172 Tm, 169 Yb, 175 Yb, 177 Lu, 105 Rh, 103m Rh, 195m Pt, 111 Ag, 124 I, 131 I, 121 At, 99m Tc, 203 Pb, 67 Ga, 68 Ga, 72 As, 111 In, 13m In, 97 Ru, 62 Cu, 64 Cu, 52 Fe, 52m Mn, 51 Cr, 123 I, 131 I, 75 Br, 76 Br, 77 Br, and 82 Br.

Assignments (5)
CHANGE OF NAME Recorded Apr 8, 2015
From: BIOSYNTHEMA INC.
To: ADVANCED ACCELERATOR APPLICATIONS USA, INC.
Reel/Frame 035360/0966 →
CHANGE OF NAME Recorded Aug 15, 2003
From: DISCOVERY PHARMACEUTICALS, INC.
To: BIOSYNTHEMA INC.
Reel/Frame 013880/0050 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2003
From: MALLINCKRODT INC.
To: DISCOVERY PHARMACEUTICALS, INC.
Reel/Frame 013805/0655 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2003
From: DE JONG, MARION; KRENNING, ERIC PAUL; VAN HAGEN, PETRUS MARTINUS
To: MALLINCKRODT INC.
Reel/Frame 013797/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2003
From: MALLINCKRODT INC.
To: DISCOVERY PHARMACEUTICALS
Reel/Frame 013829/0529 →